The other COVID-19 vaccines Australia is eyeballing
As debate continues over the merits and downsides of the AstraZeneca and Pfizer vaccines, two other candidates have each taken a step forward
Two more COVID-19 vaccines that could potentially be used in Australia have recorded significant landmarks.
The Australian Government has finalised a deal for 51 million doses of the vaccine being trialled locally by US company Novavax.
And Johnson & Johnson has published interim phase 1-2a trial results, which notably appear to show its plan for a single-dose vaccine is on track.
Speaking last week, chief medical officer Professor Paul Kelly said Novavax’s vaccine could be approved around the middle of 2021 as an alternative to the AstraZeneca vaccine for the general population.
